Digital Support for Supervised Exercise Therapy in Peripheral Arterial Disease

Peripheral Arterial Disease Clinical Trial

— TrackPAD  

Official title:

Supervised Exercise Therapy Using Mobile Health Technology in Patients With Peripheral Arterial Disease: Randomized Controlled Pilot Trial.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04947228
• Other study ID #: 18-8355-BO
• Status: Completed
• Phase: N/A
• Start date: December 6, 2018
• Est. completion date: April 30, 2019

Study information

• Verified date: June 2021
• Source: University Hospital, Essen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The individual restrictions of daily life for patients with PAD are more important than statistical facts for mortality and morbidity. Intermittent claudication causes a progressive reduction of the pain-free walking distance (PWD) as an expression of a worsening PAD. This decrease in physical capability results in a decline of mental health and relevantly reduces the patients' quality of life (QoL). Supervised exercise therapy (SET) is a cornerstone in the conservative management of intermittent claudication and extends the PWD. Even though SET is easy to practice and highly cost effective, the adherence to perform SET on a regular base is rather low. The underuse of exercise can be partly explained by the lack of institutional resources, but also by both patients' and physicians' lack of interest in exercise. Mobile health (mHealth) technologies increase the incentives and provide digital support for patients with PAD on several treatment levels. They might lead to a higher adherence to exercise training and offer new scopes in patient-centered healthcare, but so far studies show opposite results. Because app stores are flooded with health and fitness apps, specific support tools are highly desired by patients with PAD and PAD-specific solutions are missing so far. Based on this background, the investigators developed a smartphone app named TrackPAD to provide PAD-specific support for SET. The TrackPAD pilot study was designed as a 2-armed randomized controlled trial and included patients with diagnosed and symptomatic PAD. Patients were randomized by the Center for Clinical Studies in Essen using the TENALEA software into 2 groups. The control group included participants with standard care and no further mobile intervention. The intervention group included participants with standard care and additional mHealth-based self-tracking of their physical activity using trackPAD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 30, 2019
• Est. primary completion date: March 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of lower extremity PAD based on (and/or):
• ABI = 0.9 in at least one legs
• Invasive or non-invasive imaging of stenotic lower extremity artery disease
• Endovascular or surgical revascularization of lower extremity artery
• PAD Fontaine Stage IIa/b
• Smartphone with possibility to use TrackPAD: Android = 5.0 or IOS = 11.0
• Written informed consent prior to any study procedures, including a specified follow-up evaluation
• Best-medical treatment in the last 2 months in accordance with standard guidelines

Exclusion Criteria:

• Wheelchair bound, use of walking aid or walking impairment due to another cause than PAD
• Below or above knee amputation
• Acute or critical limb ischemia
• PAD Fontaine Stage I or III / IV
• No German knowledge
• Severe cognitive dysfunction
• Congestive heart failure with NYHA III-IV symptoms
• Active congestive heart failure requiring the initiation or uptitration of diuretic therapy
• Angina pectoris with CCS class 3-4 symptoms or myocardial infarction or stroke in the last 3 months
• Active arrhythmia requiring the initiation or uptitration of anti-arrhythmic therapy
• Severe valve disease

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• trackPAD
TrackPAD is a smartphone app to provide PAD-specific support for SET

Locations

Country	Name	City	State
Germany	Department of Cardiology and Vascular Medicine	Essen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Essen

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Paldán K, Simanovski J, Ullrich G, Steinmetz M, Rammos C, Jánosi RA, Moebus S, Rassaf T, Lortz J. Feasibility and Clinical Relevance of a Mobile Intervention Using TrackPAD to Support Supervised Exercise Therapy in Patients With Peripheral Arterial Disease: Study Protocol for a Randomized Controlled Pilot Trial. JMIR Res Protoc. 2019 Jun 26;8(6):e13651. doi: 10.2196/13651. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change in 6-minutes walking distance	measured via GPS with the trackPAD app	baseline, 3 months follow-up
Secondary	change in physical activity, measured in patients' self-report on how many days a week on average they engage in a physical activity that causes them to sweat or get out of breath, and how many minutes on average they spend doing it.	to compare the two groups groups in terms of physical endurance, the self-reported physical activity was recorded	baseline, 3 months follow-up
Secondary	peripheral arterial disease-related quality of life	measured with the Peripheral artery disease Quality of Life Questionnaire (PADQOL) questionnaire, a validated PAD-specific questionnaire. Minimum score is 38 and maximum is 228, with higher values indicating a better outcome.	baseline, 3 months follow-up
Secondary	Usability of the TrackPAD app	measured with the User version of the Mobile Application Rating Scale (uMars) questionnaire. The uMARS includes 3 factors, namely app quality, app subjective quality and perceived impact. Minimum score of the app quality scale is 4 and the maximum is 20. The App Subjective Quality scale has a minimum of 4 and a maximum of 20, and the Perceived Impact scale has a minimum of 6 and a maximum of 30. Higher values indicate a better outcome.	baseline, 3 months follow-up